EMA Authorised: Orkambi (Lumacaftor;ivacaftor) — Vertex Pharmaceuticals (Ireland) Limited

View source ↗

Summary

The European Medicines Agency authorised Orkambi (lumacaftor/ivacaftor) for cystic fibrosis, with Vertex Pharmaceuticals (Ireland) Limited as the marketing auth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ORKAMBI (lumacaftor and ivacaftor)

Snippet

Status: Authorised. Therapeutic area: Cystic Fibrosis. MAH: Vertex Pharmaceuticals (Ireland) Limited. Decision date: 30/10/2025